Literature DB >> 14600309

Integrated treatment of schizophrenia.

Roshel Lenroot1, Juan R Bustillo, John Lauriello, Samuel J Keith.   

Abstract

The importance of combining psychosocial and pharmacologic interventions for optimum outcome in the treatment of schizophrenia is now well recognized. However, less research is available on ways in which the two types of treatment may affect each other. This article reviews research and principles applying to the integrated use of current psychosocial and pharmacologic treatments for schizophrenia. Emphasis is placed on areas of interaction, including patient adherence and the effect of antipsychotic medications on cognitive functioning. Recommendations are presented for specific clinical situations.

Entities:  

Mesh:

Year:  2003        PMID: 14600309     DOI: 10.1176/appi.ps.54.11.1499

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  12 in total

Review 1.  Recovery in schizophrenia: reality or mere slogan.

Authors:  Natalie B Slopen; Patrick W Corrigan
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

2.  Quality of care indicators for schizophrenia: determinants of observed variations among Italian Departments of Mental Health. Results from the ETAS DSM study.

Authors:  G Fantini; G Tibaldi; P Rucci; D Gibertoni; M Vezzoli; L Cifarelli; R Tiraferri; C Munizza
Journal:  Epidemiol Psychiatr Sci       Date:  2016-03-28       Impact factor: 6.892

Review 3.  Managing suicide risk in patients with schizophrenia.

Authors:  John Kasckow; Kandi Felmet; Sidney Zisook
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

4.  Suicidal behavior in the older patient with schizophrenia.

Authors:  John Kasckow; Lori Montross; Laurie Prunty; Lauren Fox; Sidney Zisook
Journal:  Aging health       Date:  2011-06

5.  Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning.

Authors:  John Kasckow; Nicole Lanouette; Thomas Patterson; Ian Fellows; Shahrokh Golshan; Ellen Solorzano; Sidney Zisook
Journal:  Int J Geriatr Psychiatry       Date:  2010-02       Impact factor: 3.485

6.  Defining the minimal clinically important difference (MCID) of the Heinrichs-carpenter quality of life scale (QLS).

Authors:  Bruno Falissard; Christophe Sapin; Jean-Yves Loze; Wally Landsberg; Karina Hansen
Journal:  Int J Methods Psychiatr Res       Date:  2015-08-04       Impact factor: 4.035

7.  Frequency and effects of psychosocial interventions additional to olanzapine treatment in routine care of schizophrenic patients.

Authors:  Michael Linden; Lena Pyrkosch; Hans-Peter Hundemer
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-05       Impact factor: 4.328

8.  Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics.

Authors:  Hong Liu-Seifert; Haya Ascher-Svanum; Olawale Osuntokun; Kai Yu Jen; Juan Carlos Gomez
Journal:  BMC Psychiatry       Date:  2011-05-17       Impact factor: 3.630

9.  Empirically driven definitions of "good," "moderate," and "poor" levels of functioning in the treatment of schizophrenia.

Authors:  Haya Ascher-Svanum; Diego Novick; Josep Maria Haro; Jaume Aguado; Zhanglin Cui
Journal:  Qual Life Res       Date:  2012-12-14       Impact factor: 4.147

Review 10.  A systematic review of the international published literature relating to quality of institutional care for people with longer term mental health problems.

Authors:  Tatiana L Taylor; Helen Killaspy; Christine Wright; Penny Turton; Sarah White; Thomas W Kallert; Mirjam Schuster; Jorge A Cervilla; Paulette Brangier; Jiri Raboch; Lucie Kalisová; Georgi Onchev; Hristo Dimitrov; Roberto Mezzina; Kinou Wolf; Durk Wiersma; Ellen Visser; Andrzej Kiejna; Patryk Piotrowski; Dimitri Ploumpidis; Fragiskos Gonidakis; José Caldas-de-Almeida; Graça Cardoso; Michael B King
Journal:  BMC Psychiatry       Date:  2009-09-07       Impact factor: 3.630

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.